Newsroom

Newsroom · Spinal muscular atrophy (SMA) ·

SMA: FDA Approves Isembyld, a Muscle-Targeted Medicine

In short: On September 11, 2026 the FDA approved Isembyld (apitegromab), made by Scholar Rock, for spinal muscular atrophy (SMA) in people 2 and older who already take an SMN2-targeted treatment. It is described as the first SMA medicine aimed at muscle. It is an add-on, not a cure, and the label warns of fractures.

SMA: FDA Approves Isembyld, a Muscle-Targeted Medicine

What was approved

The FDA approved Isembyld (apitegromab) on September 11, 2026. The FDA label says it is for SMA in adults and children 2 years of age and older who are currently receiving a survival motor neuron 2 (SMN2)-targeted treatment, such as nusinersen or risdiplam.

Scholar Rock is the company that makes it. The recommended dose is 10 mg per kilogram of body weight, given as an intravenous infusion over about 60 minutes once every 4 weeks. This post draws on the FDA label, with the approval details also reported by NeurologyLive and the Muscular Dystrophy Association (MDA).

How it works

Isembyld is a lab-made antibody that targets the precursor forms of myostatin, a protein that limits muscle growth. Existing SMN2 treatments act on the nerve-cell side of SMA. Isembyld is meant to be used alongside them, to support muscle.

What the SAPPHIRE trial showed

The approval rests on SAPPHIRE, a Phase 3 placebo-controlled trial of 188 people with SMA, as reported by NeurologyLive. The main comparison was in children aged 2 to 12. After one year, those on the recommended dose improved by 2.2 points more than placebo on the HFMSE, a 66-point scale of motor function. The FDA label calls this a nominally statistically significant effect.

NeurologyLive also reports that 34.2% of treated children gained 3 or more points, compared with 13.5% on placebo. A gain of a few points on this scale is a modest change, and the trial does not show that people recover lost function.

Safety and the fracture warning

  • The label warns that Isembyld may increase the risk of fractures, including serious ones.
  • In the trial, 5 of 53 people (9%) on the recommended dose had a fracture, compared with 1 person (2%) on placebo. Femur fractures occurred in three people on the drug.
  • Most people who had fractures already had low bone density, earlier fractures or joint contractures. Some fractures had no clear cause such as a fall.
  • The most common side effects included upper respiratory infections, vomiting, cough, other viral infections, headache, gastroenteritis, sore throat and hypersensitivity.

What it means for people with SMA

Isembyld is a new option on top of existing SMN2 treatments, aimed at the muscle weakness that can remain. Whether it suits a given person depends on age, bone health and other factors, and that is a question for the SMA care team. It does not replace nusinersen or risdiplam, and it does not fix the underlying genetic cause.

Frequently asked questions

Is there a cure for SMA?

No. Isembyld is an add-on for people already taking an SMN2-targeted treatment. It is not described as a cure, and it does not replace those treatments.

Who can take Isembyld?

The FDA label covers adults and children 2 years and older with SMA who are currently receiving an SMN2-targeted treatment. The main trial result was in children aged 2 to 12, so how much benefit older people get is less clear from the sources read for this post.

What are the risks of Isembyld?

The label warns of fractures, including serious ones such as femur fractures. In the trial, 9% on the recommended dose had a fracture versus 2% on placebo. Anyone considering it should talk with their neurologist about bone health.

Read the full Spinal muscular atrophy (SMA) report: latest studies, treatments, trials near you, expert care centers and support groups, updated daily.

Sources

More from the newsroom

This post was written with AI from the sources listed above and has not been reviewed by a doctor. It is not medical advice. Talk with your doctor before changing treatment. See our Terms of Use.